Innovita Research Foundation

I.R.F. / Aging news / General / 11012501

MSCs Can Help to Reduce Transplant Rejection Risk
Posted on: January 25, 2011

Transplantation of marrow-derived mesenchymal stem cells (MSCs), expanded by culture in addition to whole bone marrow, has been shown to enhance engraftment of human hematopoietic stem cells (HSCs). Scientists held hypothesis that there might be an optimum ratio range that could enhance engraftment.

They examined the percent donor chimerism according to the ratio of HSCs to MSCs in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. They tested a series of ratios of co-transplanted CD34(+) -selected bone marrow cells, and marrow-derived MSCs into sublethally irradiated NOD/SCID mice.

In all experiments, 1 × 105 bone marrow derived human CD34(+) cells were administered to each mouse and human MSCs from different donors were infused concomitantly. They repeated the procedure three times and evaluated engraftment with flow cytometry four weeks after each transplantation. Serial ratios of HSCs to MSCs were 1:0, 1:1, 1:2 and 1:4, in the first experiment, 1:0, 1:1, 1:2, 1:4 and 1:8 in the second and 1:0, 1:1, 1:4, 1:8 and 1:16 in the third. Cotransplantation of HSCs and MSCs enhanced engraftment as the dose of MSCs increased.

Results suggest that the optimal ratio of HSCs and MSCs for cotransplantation might be in the range of 1:8-1:16; whereas, an excessive dose of MSCs might decrease engraftment efficiency.

Source: Kim DH, Yoo KH, Yim YS, et al.; Cotransplanted bone marrow derived mesenchymal stem cells (MSC) enhanced engraftment of hematopoietic stem cells in a MSC-dose dependent manner in NOD/SCID mice.; J Korean Med Sci. 2006 Dec;21(6):1000-4.
< Previous |  Next >